Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELVNNASDAQ:INVANASDAQ:PGENNASDAQ:RCKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELVNEnliven Therapeutics$18.62-1.6%$19.31$13.30▼$30.03$912.21M1.03262,712 shs47,003 shsINVAInnoviva$18.61+1.2%$17.76$14.95▼$21.28$1.17B0.48632,822 shs131,921 shsPGENPrecigen$1.58+1.6%$1.60$0.65▼$2.17$463.12M1.71.24 million shs308,691 shsRCKTRocket Pharmaceuticals$7.28+1.6%$7.57$4.55▼$26.98$777.87M11.33 million shs577,050 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELVNEnliven Therapeutics+3.84%+16.58%-10.25%-10.12%+10.07%INVAInnoviva+0.77%+0.55%+1.10%-2.18%+20.45%PGENPrecigen+3.33%+13.14%-2.52%+22.05%+9.93%RCKTRocket Pharmaceuticals-0.97%-0.14%-5.67%-32.33%-67.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELVNEnliven Therapeutics2.2499 of 5 stars3.60.00.00.02.84.20.0INVAInnoviva4.1876 of 5 stars3.50.00.04.22.92.51.9PGENPrecigen3.6833 of 5 stars3.50.00.04.72.71.70.6RCKTRocket Pharmaceuticals4.633 of 5 stars4.51.00.04.72.05.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELVNEnliven Therapeutics 3.25Buy$40.33116.67% UpsideINVAInnoviva 3.00Buy$55.00195.62% UpsidePGENPrecigen 3.00Buy$7.00344.44% UpsideRCKTRocket Pharmaceuticals 2.92Moderate Buy$43.00490.98% UpsideCurrent Analyst Ratings BreakdownLatest PGEN, RCKT, INVA, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025RCKTRocket PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/21/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $39.003/20/2025PGENPrecigenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/12/2025RCKTRocket PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$50.003/7/2025INVAInnovivaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$55.003/3/2025RCKTRocket PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $15.003/3/2025RCKTRocket PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$51.00 ➝ $52.003/3/2025RCKTRocket PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $36.002/28/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$62.00 ➝ $54.002/28/2025RCKTRocket PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$52.00 ➝ $42.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELVNEnliven TherapeuticsN/AN/AN/AN/A$5.97 per shareN/AINVAInnoviva$358.71M3.25$3.60 per share5.17$10.66 per share1.75PGENPrecigen$3.93M117.99N/AN/A$0.48 per share3.28RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELVNEnliven Therapeutics-$71.58M-$1.89N/AN/AN/AN/A-29.46%-27.33%5/13/2025 (Estimated)INVAInnoviva$179.72M$0.1926.9612.00N/A18.31%20.84%11.38%5/6/2025 (Estimated)PGENPrecigen-$95.90M-$0.48N/AN/AN/A-3,521.68%-123.06%-87.33%5/13/2025 (Estimated)RCKTRocket Pharmaceuticals-$245.60M-$2.73N/AN/AN/AN/A-62.62%-54.17%5/5/2025 (Estimated)Latest PGEN, RCKT, INVA, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ELVNEnliven Therapeutics-$0.51N/AN/AN/AN/AN/A5/13/2025Q1 2025PGENPrecigen-$0.08N/AN/AN/A$0.50 millionN/A5/5/2025Q1 2025RCKTRocket Pharmaceuticals-$0.59N/AN/AN/A$0.80 millionN/A3/19/2025Q4 2024PGENPrecigen-$0.06-$0.04+$0.02-$0.06$1.30 million$1.19 million3/13/2025Q4 2024ELVNEnliven Therapeutics-$0.53-$0.46+$0.07-$0.46N/A$0.03 million3/3/2025Q4 2024RCKTRocket Pharmaceuticals-$0.68-$0.62+$0.06-$0.62$0.03 millionN/A2/26/2025Q4 2024INVAInnovivaN/A$0.57N/A$0.26N/A$91.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELVNEnliven TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELVNEnliven TherapeuticsN/A17.4417.44INVAInnoviva0.381.791.64PGENPrecigenN/A1.631.63RCKTRocket Pharmaceuticals0.066.056.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELVNEnliven Therapeutics95.08%INVAInnoviva99.12%PGENPrecigen33.51%RCKTRocket Pharmaceuticals98.39%Insider OwnershipCompanyInsider OwnershipELVNEnliven Therapeutics29.20%INVAInnoviva2.25%PGENPrecigen44.90%RCKTRocket Pharmaceuticals28.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELVNEnliven Therapeutics5049.00 million34.59 millionOptionableINVAInnoviva10062.68 million61.54 millionOptionablePGENPrecigen190294.04 million161.37 millionOptionableRCKTRocket Pharmaceuticals240106.63 million65.18 millionOptionablePGEN, RCKT, INVA, and ELVN HeadlinesRecent News About These CompaniesRenaissance Technologies LLC Acquires Shares of 218,519 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)April 27 at 3:45 AM | marketbeat.com48,400 Shares in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Bought by NatixisApril 26 at 5:17 AM | marketbeat.comMarshall Wace LLP Purchases 446,662 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)April 26 at 4:32 AM | marketbeat.comRocket Lab USA takes aim at SpaceX with Neutron RocketApril 25, 2025 | msn.comTickets to Rocket Classic, Detroit's PGA Tour stop, now on saleApril 25, 2025 | detroitnews.comWarriors' Steve Kerr shares disappointment in Rocket's fans chants toward Draymond GreenApril 25, 2025 | msn.comRed Rocket starts operations at two 144 MW wind farmsApril 25, 2025 | engineeringnews.co.zaRocket Report: The pitfalls of rideshare; China launches next Tiangong crewApril 25, 2025 | arstechnica.comWhy Is Rocket Lab Stock Trading Higher On Thursday?April 24, 2025 | benzinga.comRocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 3.6% - Time to Sell?April 24, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 8.9% - Here's What HappenedApril 23, 2025 | marketbeat.comAvoro Capital Advisors LLC Buys New Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)April 23, 2025 | marketbeat.comVoss Capital LP Makes New Investment in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)April 23, 2025 | marketbeat.comGeode Capital Management LLC Increases Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)April 21, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Alliancebernstein L.P.April 21, 2025 | marketbeat.comWalleye Capital LLC Has $2.77 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)April 20, 2025 | marketbeat.comJPMorgan Chase & Co. Sells 41,024 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)April 20, 2025 | marketbeat.comXTX Topco Ltd Has $800,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)April 19, 2025 | marketbeat.comOilers' Leon Draisaitl Notches First Career Rocket Richard TrophyApril 18, 2025 | msn.comRocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 7.5% - Here's WhyApril 18, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Synovus Financial CorpApril 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePGEN, RCKT, INVA, and ELVN Company DescriptionsEnliven Therapeutics NASDAQ:ELVN$18.61 -0.30 (-1.56%) As of 01:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Innoviva NASDAQ:INVA$18.60 +0.23 (+1.22%) As of 01:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Precigen NASDAQ:PGEN$1.58 +0.03 (+1.61%) As of 01:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Rocket Pharmaceuticals NASDAQ:RCKT$7.28 +0.12 (+1.62%) As of 01:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
